CERo Therapeutics appoints Chris Ehrlich as permanent CEO

CERO THERAPEUTICS HOLDINGS, INC.

Chris Ehrlich appointed permanent CEO effective Dec 2, 2024, was interim since Oct 2.
Company plans to file IND for CER-1236 in solid tumors (ovarian, NSCLC) in H1 2025.
Ehrlich also serves as CEO of Launch One Acquisition Corp.
Ehrlich brings biotech leadership experience including prior SPAC mergers and venture capital.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.